BETA Technologies launches IPO of 25 million shares priced $27-$33
Investing.com - H.C. Wainwright has reiterated a Buy rating and $59.00 price target on AnaptysBio (NASDAQ:ANAB), currently trading at $31.85, following a company webinar focused on its CD122 antagonist, ANB033. The stock has shown remarkable momentum, gaining 76% over the past six months. According to InvestingPro data, analyst price targets range from $20 to $90.
The webinar, held after market close on Tuesday, highlighted ANB033’s development for celiac disease (CeD). The drug targets CD122, the beta subunit of the receptor for IL-15 and IL-2 cytokines, which are overexpressed in celiac disease intraepithelial lymphocytes and gut tissue. With a market capitalization of $892 million and a strong liquidity position, InvestingPro analysis shows AnaptysBio maintains a healthy balance sheet despite ongoing R&D investments.
ANB033 works by inhibiting both IL-15 and IL-2, differentiating it from other IL-15-only targeting approaches. In preclinical studies, ANB033 preserved villus height and crypt depth in a celiac disease mouse model when administered with gluten, while control subjects showed the expected decline in these measurements.
The drug demonstrated ability to preserve CD8+ intraepithelial lymphocytes in the small intestine without increasing inflammatory markers. H.C. Wainwright noted ANB033 showed superior reduction in T cell proliferation compared to competing assets.
Two other CD122 antagonists are currently in development: Forte’s FB102, which has shown positive proof-of-concept data in Phase 1b celiac disease trials, and Incyte’s auremolimab, which is in Phase 1b development for vitiligo. AnaptysBio’s stock typically moves counter to market trends with a beta of -0.17, making it an interesting portfolio diversification option. Discover more insights and 8 additional ProTips with InvestingPro.
In other recent news, AnaptysBio announced that it will present complete data from its Phase 2b trial of rosnilimab in rheumatoid arthritis at the American College of Rheumatology Convergence 2025. This presentation will focus on the drug’s efficacy and safety profile. Meanwhile, Piper Sandler has raised its price target for AnaptysBio to $72, citing the success of JEMPERLI, a drug partnered with GSK, as a major factor. Barclays also initiated coverage on AnaptysBio with an Overweight rating and a $78 price target, highlighting the potential of rosnilimab. Additionally, Leerink Partners increased its price target to $37 following AnaptysBio’s announcement of its plan to separate into two independent companies by the end of 2026. H.C. Wainwright also raised its price target to $59, maintaining a Buy rating, in light of this planned separation into a Biopharma operation and a Royalty Management business. These developments indicate significant interest and activity around AnaptysBio’s recent strategic moves and product pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.